We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App





Regeneron’s Next-Gen COVID-19 Monoclonal Antibodies Active Against All Known VOCs, Including Omicron and Delta

By HospiMedica International staff writers
Posted on 17 Dec 2021
Print article
Illustration
Illustration

Regeneron Pharmaceuticals, Inc.’s (Tarrytown, NY, USA) next generation monoclonal antibodies are active against all known SARS-CoV-2 variants of concern, including both Omicron and Delta.

Regeneron has confirmed that multiple ‘next generation’ monoclonal antibodies from its large collection of fully human monoclonal antibodies targeting SARS-CoV-2 are active against the Omicron (B.1.1.529) and Delta (B.1.617.2) variants, as well as against the other variants of concern. Pending regulatory discussions, the company anticipates entering the clinic in the first quarter of 2022.

According to Regeneron, its currently authorized REGEN-COV antibodies (casirivimab and imdevimab) have diminished potency against Omicron, but are active against Delta, which currently is the most prevalent variant in the US. REGEN-COV is a cocktail of two monoclonal antibodies that was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19, using Regeneron's proprietary VelocImmune and VelociSuite technologies. The two potent, virus-neutralizing antibodies that form the cocktail bind non-competitively to the critical receptor binding domain of the virus's spike protein, which diminishes the ability of mutant viruses to escape treatment and protects against most spike variants that have arisen in the human population. REGEN-COV has not been approved by the FDA, but is currently authorized for emergency use for the treatment and post-exposure prophylaxis in certain high risk individuals.

Related Links:
Regeneron Pharmaceuticals, Inc. 


Print article

Channels

Surgical Techniques

view channel
Image: Persona IQ is a first-to-world smart implant that captures key kinematic data metrics (Photo courtesy of Zimmer Biomet)

World’s First Smart Knee Implant Optimizes Patient Monitoring and Recovery After Surgery

A first-to-world smart knee implant utilizes sensor-based technology to allow physicians and care teams to collect patient-specific kinematic data during the course of patient monitoring.... Read more

Patient Care

view channel
Image: The biomolecular film can be picked up with tweezers and placed onto a wound (Photo courtesy of TUM)

Biomolecular Wound Healing Film Adheres to Sensitive Tissue and Releases Active Ingredients

Conventional bandages may be very effective for treating smaller skin abrasions, but things get more difficult when it comes to soft-tissue injuries such as on the tongue or on sensitive surfaces like... Read more

Health IT

view channel
Image: AI can reveal a patient`s heart health (Photo courtesy of Mayo Clinic)

AI Trained for Specific Vocal Biomarkers Could Accurately Predict Coronary Artery Disease

Earlier studies have examined the use of voice analysis for identifying voice markers associated with coronary artery disease (CAD) and heart failure. Other research groups have explored the use of similar... Read more

Business

view channel
Image: The global capsule endoscopy system market is growing at a rapid pace (Photo courtesy of Pexels)

Capsule Endoscopy System Market Driven by Rising Preference for Minimally Invasive Screening Procedure

Capsule endoscopy is generally a non-invasive technique that enables complete examination of the gastrointestinal tract with the use of the disposable and wireless device known as the video capsule.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.